170 related articles for article (PubMed ID: 28130055)
1. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
2. Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling.
Ruggieri R; Stavreva N; Naccarato S; Stavrev P
Phys Med Biol; 2013 Jul; 58(13):4611-20. PubMed ID: 23771131
[TBL] [Abstract][Full Text] [Related]
3. Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.
Liu F; Tai A; Lee P; Biswas T; Ding GX; El Naqa I; Grimm J; Jackson A; Kong FS; LaCouture T; Loo B; Miften M; Solberg T; Li XA
Radiother Oncol; 2017 Feb; 122(2):286-294. PubMed ID: 27871671
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.
Klement RJ; Sonke JJ; Allgäuer M; Andratschke N; Appold S; Belderbos J; Belka C; Dieckmann K; Eich HT; Flentje M; Grills I; Eble M; Hope A; Grosu AL; Semrau S; Sweeney RA; Hörner-Rieber J; Werner-Wasik M; Engenhart-Cabillic R; Ye H; Guckenberger M
Radiother Oncol; 2020 Jan; 142():210-216. PubMed ID: 31431371
[TBL] [Abstract][Full Text] [Related]
5. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia.
Ruggieri R; Naccarato S; Nahum AE
Acta Oncol; 2010 Nov; 49(8):1304-14. PubMed ID: 20500031
[TBL] [Abstract][Full Text] [Related]
6. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
7. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
[TBL] [Abstract][Full Text] [Related]
8. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
[TBL] [Abstract][Full Text] [Related]
9. The radiobiology of hypofractionation.
Nahum AE
Clin Oncol (R Coll Radiol); 2015 May; 27(5):260-9. PubMed ID: 25797579
[TBL] [Abstract][Full Text] [Related]
10. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
[TBL] [Abstract][Full Text] [Related]
11. Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.
Lindblom E; Antonovic L; Dasu A; Lax I; Wersäll P; Toma-Dasu I
Radiat Oncol; 2014 Jun; 9():149. PubMed ID: 24974778
[TBL] [Abstract][Full Text] [Related]
12. Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.
Lindblom E; Dasu A; Toma-Dasu I
Acta Oncol; 2015; 54(9):1592-8. PubMed ID: 26217986
[TBL] [Abstract][Full Text] [Related]
13. Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.
Huang BT; Lin Z; Lin PX; Lu JY; Chen CZ
Oncotarget; 2016 Jun; 7(26):40746-40755. PubMed ID: 27203739
[TBL] [Abstract][Full Text] [Related]
14. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
[TBL] [Abstract][Full Text] [Related]
15. A radiobiological model of reoxygenation and fractionation effects.
Guerrero M; Carlson DJ
Med Phys; 2017 May; 44(5):2002-2010. PubMed ID: 28273349
[TBL] [Abstract][Full Text] [Related]
16. Optimal tumour control for early-stage non-small-cell lung cancer: A radiobiological modelling perspective.
Alaswad M; Kleefeld C; Foley M
Phys Med; 2019 Oct; 66():55-65. PubMed ID: 31561206
[TBL] [Abstract][Full Text] [Related]
17. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma.
Liu F; Brown DR; Munley MT
Radiother Oncol; 2024 May; 194():110223. PubMed ID: 38467342
[TBL] [Abstract][Full Text] [Related]
18. Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes.
Chvetsov AV; Hanin LG; Stewart RD; Zeng J; Rengan R; Lo SS
Phys Med Biol; 2021 Jun; 66(12):. PubMed ID: 34030139
[TBL] [Abstract][Full Text] [Related]
19. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
[TBL] [Abstract][Full Text] [Related]
20. Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
Santiago A; Barczyk S; Jelen U; Engenhart-Cabillic R; Wittig A
Radiat Oncol; 2016 May; 11():67. PubMed ID: 27154064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
